June 2, 2026 — The antibody-drug conjugate (ADC) sector is undergoing a structural transformation. In recent weeks, Bristol Myers Squibb's exclusive licensing of Lonza's SYNtecan™ linker-payload platform and a strategic collaboration between Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services signal that ADC manufacturing is moving decisively toward platform-based models — with profound implications for API and intermediate suppliers.
On May 7, 2026, Bristol Myers Squibb and Lonza announced an exclusive single-target licensing deal granting BMS access to Lonza's SYNtecan™ linker-payload platform for ADC development. The deal also includes Lonza's GlycoConnect® conjugation technology and HydraSpace® spacer technology, originally acquired through the 2023 Synaffix acquisition.
BMS will handle research, development, manufacturing, and commercialization. Lonza receives upfront payments, milestones, and royalties — a structure where CDMOs retain economic upside through the entire product lifecycle. For API suppliers, this creates a technology transfer chain requiring specialized linker-payload intermediates with tighter purity profiles and multi-year supply agreements once platforms lock into commercial manufacturing.
Piramal Pharma Solutions — the world's first FDA-approved ADC CDMO with over 20 years of experience — announced a collaboration with Ajinomoto Bio-Pharma Services. The arrangement enables mutual customer referrals for ADC development, with Piramal gaining access to Ajinomoto's AJICAP™ site-specific conjugation technology through a Material Transfer Agreement.
AJICAP™ simplifies site-specific ADC creation, lowering barriers for early-stage developers. Combined with Piramal's recently achieved milestone of its 1,500th ADC batch at the Grangemouth facility, this creates a direct pipeline from platform technology to commercial manufacturing — generating new demand for linker molecules, payload compounds, and conjugation reagents.
Recent technical advances are changing ADC economics. BioDlink's published research demonstrated one-step ADC manufacturing achieving over 95% conjugation yield in under one hour — dramatically faster than traditional multi-step processes requiring days. Higher yield processes reduce raw material consumption per unit, while glycoengineering approaches create new product categories for suppliers specializing in glycan-modified antibodies and conjugation reagents.
The surge in ADC activity is driving unprecedented capacity growth. Samsung Biologics completed its acquisition of GSK's Rockville, Maryland facility, adding 60,000 liters and reaching 845,000 liters total global capacity. Cambrex announced $120 million in API manufacturing expansion in Iowa, including 140,000 liters for complex chemistry and HPAPIs. Hovione is debuting a $100 million spray drying expansion in New Jersey for solubility-enhanced ADC formulations.
For suppliers, these expansions signal growing demand but also vertical integration risk as CDMOs bring more supply chain functions in-house.
The convergence of platform deal-making and capacity expansion creates several imperatives: suppliers should align portfolios with emerging ADC platforms (SYNtecan™, AJICAP™, ThioBridge™); invest in HPAPI expertise and containment infrastructure; develop linker chemistry specialization for site-specific conjugation; build multi-regional capabilities for the geographically dispersed ADC manufacturing network; and strengthen regulatory infrastructure with sophisticated DMF filings and stability documentation for commercial-stage supply agreements.
The ADC market is projected to exceed $30 billion by 2030, supported by over 300 programs in clinical development. The shift toward platform-based manufacturing is accelerating timelines and lowering barriers. For API and intermediate suppliers, the window for early engagement with ADC platform developers is narrowing — companies investing now in platform-compatible chemistries, HPAPI capabilities, and global regulatory readiness will capture disproportionate share in this high-growth segment.
